Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Virology"
DOI: 10.1128/jvi.02222-17
Abstract: Understanding the protective principles that lead to a safe, effective vaccine against HIV in nonhuman primate (NHP) models requires test viruses that allow the evaluation of anti-HIV envelope responses. Reduced HIV acquisition risk in RV144… read more here.
Keywords: rhesus; hiv; rv144; shiv e1p5 ... See more keywords
IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees
Sign Up to like & getrecommendations! Published in 2020 at "JCI Insight"
DOI: 10.1172/jci.insight.140925
Abstract: While the RV144 HIV vaccine trial led to moderately reduced risk of HIV acquisition, emerging data from the HVTN702 trial point to the critical need to reexamine RV144-based correlates of reduced risk of protection. While… read more here.
Keywords: igg1; iga; igg3; rv144 ... See more keywords
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial
Sign Up to like & getrecommendations! Published in 2017 at "PLoS Pathogens"
DOI: 10.1371/journal.ppat.1006182
Abstract: The canary pox vector and gp120 vaccine (ALVAC-HIV and AIDSVAX B/E gp120) in the RV144 HIV-1 vaccine trial conferred an estimated 31% vaccine efficacy. Although the vaccine Env AE.A244 gp120 is antigenic for the unmutated… read more here.
Keywords: trial; hiv; rv144; vaccine ... See more keywords